Product candidate FPI-1434, when administered with olaparib,
resulted in enhanced efficacy against colorectal and lung cancer
xenografts
Combination of IGF-1R targeted alpha therapy with immune
checkpoint inhibitors demonstrated enhanced efficacy in colorectal
cancer models
Data featured in e-poster sessions at the 2021 AACR Virtual
Annual Meeting
HAMILTON, ON and BOSTON, April
10, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc.
(Nasdaq: FUSN), a clinical-stage oncology company focused on
developing next-generation radiopharmaceuticals as precision
medicines, today announced the presentation of preclinical data at
the 2021 American Association for Cancer Research (AACR) Virtual
Annual Meeting. The posters will be presented during the
Preclinical Radiotherapeutics and Combination Immunotherapies
sessions taking place today. The posters highlight the potential of
Fusion's targeted alpha therapies (TATs) to enable delivery of an
alpha particle emitting isotope (actinium-225) as both
monotherapies and combination therapies across multiple tumor
types.
"These data are the result of Fusion's early investments in
research to understand the power of combining our potent TATs with
the latest generation of cancer therapies, such as checkpoint
inhibitors and DNA damage response inhibitors (DDRis), and they
reinforce our belief in the potential of our pipeline of TATs to
redefine the utility of radiopharmaceuticals in the cancer
treatment paradigm," said Fusion Chief Executive Officer
John Valliant, Ph.D. "We believe we
have an opportunity to advance clinical development of our product
candidate FPI-1434 as monotherapy and in combination with these
novel agents, leading to more treatment options for patients in
earlier lines of therapy."
In one set of preclinical studies, highlighted in poster number
LB130 titled, "Combination of IGF-1R Targeted Alpha Therapy with
Olaparib Results in Synergistic Efficacy Against Colorectal and
Lung Cancer Xenografts," results demonstrated that the delivery of
alpha-particle radiation by FPI-1434 induced double-stranded DNA
breaks and apoptosis in treated colorectal cancer tumor xenografts.
Co-dosing with the PARP (poly ADP-ribose polymerase) inhibitor
olaparib resulted in lower doses required for efficacy of FPI-1434
in lung and colorectal cancer tumor xenografts, supporting the
potential clinical development of this combination.
In an additional set of preclinical studies, highlighted in
poster number LB155 titled, "Combination of IGF-1R Targeted Alpha
Therapy with Checkpoint Inhibitors Results in Synergistic Efficacy
in Colorectal Cancer Syngeneic Model," data showed that treatment
with IGF-1R TAT in combination with immune checkpoint inhibitors
resulted in complete tumor eradication. Additionally, an increase
in antigen-specific CD8 positive T cells and a strong "vaccine"
effect were observed with the combination of IGF-1R TAT and immune
checkpoint inhibitors, as noted by the prevention of tumor growth
in animals that were reinoculated with the same tumor cells.
About FPI-1434
FPI-1434 is a radioimmunoconjugate
designed to target and deliver alpha emitting medical isotopes to
cancer cells expressing IGF-1R, a receptor that is overexpressed on
many tumor types. FPI-1434 utilizes Fusion's Fast-Clear linker to
connect a human monoclonal antibody that targets IGF-1R with
actinium-225, a powerful alpha-emitting isotope with desirable
half-life and decay chain properties.
About Fusion
Fusion Pharmaceuticals is a
clinical-stage oncology company focused on developing
next-generation radiopharmaceuticals as precision medicines.
Employing a proprietary Fast-Clear linker technology, Fusion
connects alpha particle emitting isotopes to targeting molecules in
order to selectively deliver the alpha emitting payloads to tumors.
Fusion's lead program, FPI-1434, is currently in a Phase 1 clinical
trial.
Forward Looking Statements
This press release contains "forward-looking statements" for
purposes of the safe harbor provisions of The Private Securities
Litigation Reform Act of 1995, including but not limited to the
statements regarding Fusion Pharmaceuticals Inc.'s (the "Company")
future business and financial performance. For this purpose, any
statements contained herein that are not statements of historical
fact may be deemed forward-looking statements. Without limiting the
foregoing, the words "expect," "plans," "anticipates," "intends,"
"will," and similar expressions are also intended to identify
forward-looking statements, as are expressed or implied statements
with respect to the Company's potential drug candidates, including
any expressed or implied statements regarding the successful
development of product candidate FPI-1434; and the likelihood of
success of any ongoing or future clinical trials
involving product candidate FPI-1434. Actual results may
differ materially from those indicated by such forward-looking
statements as a result of risks and uncertainties, including but
not limited to the following: there can be no guarantees that the
Company will advance any clinical product candidate or other
component of its potential pipeline to the clinic, to the
regulatory process or to commercialization; management's
expectations could be affected by unexpected regulatory actions or
delays; uncertainties relating to, or unsuccessful results of,
clinical trials, including additional data relating to the ongoing
clinical trials evaluating its product candidates; the Company's
ability to obtain additional funding required to conduct its
research, development and commercialization activities; changes in
the Company's business plan or objectives; the ability of the
Company to attract and retain qualified personnel; competition in
general; and the Company's ability to obtain, maintain and enforce
patent and other intellectual property protection for its product
candidates and its discoveries. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors
that may cause actual results to be materially different from any
future results, performance or achievements expressed or implied by
such statements. These and other risks which may impact
management's expectations are described in greater detail under the
heading "Risk Factors" in the Company's quarterly report on
Form 10-K for the quarter ended December 31, 2020 as filed with the SEC and in
any subsequent periodic or current report that the Company files
with the SEC. All forward-looking statements reflect the Company's
estimates only as of the date of this release (unless another date
is indicated) and should not be relied upon as reflecting the
Company's views, expectations or beliefs at any date subsequent to
the date of this release. While Fusion may elect to update these
forward-looking statements at some point in the future, it
specifically disclaims any obligation to do so, even if the
Company's estimates change.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/fusion-pharmaceuticals-announces-preclinical-combination-data-demonstrating-enhanced-efficacy-in-multiple-preclinical-tumor-models-301266162.html
SOURCE Fusion Pharmaceuticals Inc.